WO2005095436A1 - 4-メチルエルゴスト-7-エン-3-オール骨格を有する配糖体及び高血糖改善剤 - Google Patents
4-メチルエルゴスト-7-エン-3-オール骨格を有する配糖体及び高血糖改善剤 Download PDFInfo
- Publication number
- WO2005095436A1 WO2005095436A1 PCT/JP2005/006019 JP2005006019W WO2005095436A1 WO 2005095436 A1 WO2005095436 A1 WO 2005095436A1 JP 2005006019 W JP2005006019 W JP 2005006019W WO 2005095436 A1 WO2005095436 A1 WO 2005095436A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- present
- composition
- hyperglycemia
- patent document
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J17/005—Glycosides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Definitions
- the present invention relates to a novel glycoside having a 4-methylergost-7-en-3-ol skeleton, 3-0- ⁇ -D-darcoviranosyl 4-methylergost-17-en-3-ol, and
- the present invention relates to a composition comprising the same, and a medicine or a food or beverage containing the composition.
- Non-Patent Document 1 It is known that 4-methylergost-7-en-ol is a substance existing in plants (Non-Patent Document 1).
- the prior art of this compound relates only to the biosynthetic system of oral phenol (one of the stereoisomers of 4-methylcholest 7-en-3-ol) having a structure similar to that of the compound ( Non-patent document 2), the use of these compounds was completely unknown.
- the genus Aloe of the lily family is a group of plants including aloe vera (Aloe barbadensis Miller) and squirrel aloe (Aloe arborescen Miller var. Natalensis Berger), and is empirically known to have various effects.
- Prior art relating to the use of plants includes immunomodulatory polysaccharides (Patent Document 1), immunosuppressive ameliorating agents characterized by containing butanol fraction of aloe extract or aloin (Patent Document 2), and HSP60 family.
- Patent Documents 3 to 5 There are a synthetic inhibitor containing an alroin derivative of a protein belonging thereto (Patent Documents 3 to 5), a lectin-active protein derived from aloe leaf bark (Patent Document 6), and the like.
- Non-patent Document 3 a clinical test in the United States
- Non-patent Document 4 a blood glucose lowering effect in animals
- Patent Document 7 polysaccharides in plants of the genus Allerca are disclosed (Patent Document 7)
- the blood sugar lowering component of the plants of the genus Alloe is predicted to be polysaccharides or glycoproteins.
- the peak specific to an ester group in the FT-IR chart correlates with the activity, and the active ingredient is a polysaccharide or an amino acid.
- the active ingredient is damaged in a gel solution or an aloe vera gel extract.
- the blood sugar lowering effect of aloe polysaccharide (Patent Document 9) and the antioxidant effect of 7-hydroxychromone contained in Aloe (Patent Document 10) have been disclosed.
- aloe vera leaf bark contains baroballoin and aloe-emodin which have a laxative action, and has heretofore been considered unfavorable in industry.
- Hemoglobin Ale is a conjugate of glucose and hemoglobin, and increases depending on the glucose concentration depending on the degree of hyperglycemia.Hemoglobin Ale once produced does not disappear until the end of the red blood cell life (120 days). It reflects the long-term glycemic control status of the disease (Non-Patent Document 6). Hemoglobin Ale has been adopted as a selective test in the Basic Health Examination of the Geriatric Health Act since 1996, and has been adopted as a supplementary diagnostic indicator for diabetes in the new diagnostic criteria for diabetes in 1999. Is considered to be a significant index (Non-Patent Document 7).
- Non-Patent Document 8 If the state of hyperglycemia continues, glucose-specific insulin secretion deficiency and insulin resistance are observed, which is a factor that further worsens hyperglycemia (Non-Patent Document 8).
- Diet and exercise are being promoted to control blood sugar levels in prediabetes (a condition suspected of diabetes).
- a variety of functional foods (foods for specified health use) for suppressing postprandial blood glucose elevation are already on sale, but all of them are only transient blood glucose elevation suppressing effects. Therefore, the development of this hemoglobin Ale-lowering agent has been eagerly desired, which is not expected until the control of blood glucose levels over a long period of time.
- ex-dalcosidase inhibitors as insulin secretion promoters
- thiazolidine derivatives as insulin resistance improvers
- the drug's efficacy is satisfactory, and there are many problems such as side effects that cause a coma due to a rapid drop in blood sugar.
- hemoglobin Ale can be safely taken without causing hypoglycemia.
- prior art documents include, for example, a blood sugar rise inhibitor containing a component derived from banapa (Patent Document 11) and a fermented barley product having a blood sugar rise inhibitory effect.
- a blood sugar level elevation inhibitor containing a concentrated extract as an active ingredient Patent Document 12 and the like.
- a triterpene glycoside as an active ingredient
- techniques for using a triterpene glycoside as an active ingredient include, for example, a diabetes preventive agent using a glycoside extracted from gymneminodram as an active ingredient (Patent Document 13), and extraction from banapa. Metabolic improvement method containing the selected corosolic acid as an active ingredient and a composition therefor (Patent Document 14), a lipase inhibitor (Patent Document 15), and a triterpene derivative having immunosuppressive activity (Patent Document 16) .
- Patent Document 17 in the activity of enhancing the insulin action of a compound having a lanostane skeleton or a 3,4-secolanostane skeleton (Patent Document 17), although its effect on diseases in the spleen is unknown, the effect is not limited to adipocytes. It is disclosed as enhancing the action of insulin in regulation.
- a 3-on and 24-alkylcholestane 3-on group The selected compound is disclosed as a hypoglycemic agent (Patent Document 18).
- Glycosides having a 4-methylstigmasto-7-en-3-ol skeleton which is a similar structure, include 3-O- ⁇ -D-darcoviranosyl 4-methylstigmasto-17-en-3-ol. It is reported that it is contained in Bryonia (Bryonia alba), a squash plant (Non-Patent Document 9). Nor.
- Patent Document 1 Japanese Patent Publication No. 2001-520019
- Patent Document 2 Japanese Patent Application Laid-Open No. 08-208495
- Patent Document 3 JP-A-10-120576
- Patent Document 4 JP-A-10-0445604
- Patent Document 5 JP-A-10-036271
- Patent Document 6 Japanese Patent Application Laid-Open No. 09-059298
- Patent Document 7 JP-A-60-214741
- Patent Document 8 JP-A-2003-286185
- Patent Document 9 US Pat. No. 4,559,069
- Patent Document 10 U.S. Patent Application Publication No. 2003Z0207818
- Patent Document 11 Japanese Patent Application Laid-Open No. 2003-095941
- Patent Document 12 JP-A-2002-371003
- Patent Document 13 Japanese Patent Application Laid-Open No. 05-247086
- Patent Document 14 JP-A-2002-205949
- Patent Document 15 JP-A-09-040689
- Patent Document 16 Japanese Patent Publication No. 11-511482
- Patent Document 17 JP-A-10-330266
- Patent Document 18 Japanese Patent Application Laid-Open No. 2003-048837
- Non-Patent Document 1 Chem. Pharm. Bull., 624-626, 1993
- Non-Patent Document 2 Biochemica Biophysica Acta, pp. 63-88, 2000
- Non-Patent Document 3 Phytomedicine, Vol. 3, pp. 245-248, 1996
- Non-Patent Document 4 Phytotherapy Research, Vol. 15, pp. 157-161, 2001
- Non-Patent Document 5 Phytotherapy Research, Vol. 7, pp. 37-42, 1993
- Non-patent document 6 Japanese clinical practice, volume 748, volume 1, pages 615 to 617, 1999
- Non-patent document 7 Japanese clinical practice, volume 808, volume 2, pages 405 to 409, 2002
- Non-Patent Document 8 Yoshio Yazaki, Masahiro Muramatsu, “The Forefront of Diabetes”, pp. 126-139, Yodosha, 1997
- Non-Patent Document 9 Khimiya Prirodnykh Soedinenii, Vol. 3, Soviet Union, 1977 Disclosure of the invention
- An object of the present invention is to provide a novel conjugate which can be safely ingested without causing hypoglycemia and has a long-term blood sugar level controlling effect of lowering hemoglobin Alc level.
- Another object of the present invention is to provide a method for producing a composition containing an effective amount of the compound from a raw material that can be safely ingested based on food experience and is easily available, and that does not contain an industrially undesirable component.
- the present inventors have conducted intensive studies to solve the above-described problems, and as a result, a novel glycoside extracted and purified from aloe vera (Aloe barbadensis Miller) mesophyll (transparent gel portion). 0- ⁇ -D-darcoviranosyl 4-methylergoen-1-ol can be safely ingested without causing hypoglycemia and has a long-term blood glucose control effect that lowers hemoglobin Ale level Was found. The present invention has been completed based on the above findings.
- the present invention is a compound having a structure represented by the following chemical formula (1) (hereinafter, also referred to as “compound of the present invention”).
- the present invention also provides a composition containing the compound of the present invention in an amount of 0.001% by mass or more on a dry weight basis (hereinafter, also referred to as “composition of the present invention”).
- composition of the present invention is particularly preferably that the lily plant which is preferably an extract of a lily plant or a fraction thereof is Aloe barbadensis Miller, and in an embodiment! /
- the present invention also provides a hyperglycemia improving agent (hereinafter, also referred to as “agent of the present invention”) containing the compound of the present invention or the composition of the present invention as an active ingredient.
- the present invention also provides a medicine or a food or beverage containing the hyperglycemia improving agent.
- the present invention is characterized in that it contains the compound of the present invention or the composition of the present invention as an active ingredient and has a hyperglycemic ameliorating effect, and has a label indicating that it is used for ameliorating hyperglycemia.
- the above-mentioned medicines or foods and drinks may be collectively referred to as “the medicines or foods and drinks of the present invention”.
- the present invention further relates to a method for producing the compound of the present invention or the composition of the present invention, wherein the plant contains a compound according to claim 1 or a part thereof or a crushed product thereof.
- the present invention provides a method characterized by extracting a fraction containing the same compound with an organic solvent or hot water and concentrating the same, and it is particularly preferable that the lily plant is Aloe barbadensis Miller, As an embodiment.
- the present invention also provides use of the compound of the present invention or a composition containing the same in the manufacture of a medicament for improving hyperglycemia.
- the use of the present invention is preferably such that the composition is an extract of a lily plant containing 0.001% by mass or more of the compound by dry mass or a fraction thereof. Barbadensis Miller) is a particularly preferred embodiment.
- the present invention also provides a method for improving hyperglycemia, which comprises administering a compound of the present invention or a composition comprising the same to a subject whose hyperglycemia is to be improved.
- the method of the present invention is characterized in that the composition is preferably an extract of a lily plant or a fraction thereof containing the compound in an amount of 0.001% by mass or more on a dry mass basis. Barbadensis Miller) is a particularly preferred embodiment.
- FIG. 1 is a GC-MS spectrum of an acetylated form of the aglycone moiety of the glycoside of the present invention (a photograph substituted for a drawing: a halftone image displayed on a display).
- FIG. 2 is a 13 C-NMR chart of an acetylated form of the aglycone moiety of the glycoside of the present invention (a photograph substituted for a drawing: a halftone image displayed on a display).
- FIG. 3 is a graph showing a time-dependent change in normal blood glucose level of a mouse to which the compound of the present invention has been administered.
- FIG. 4 is a graph showing the time course of fasting blood glucose levels of mice administered with the compound of the present invention.
- the compound of the present invention is a compound having a structure represented by the chemical formula (1), that is, 3-0.
- the compound of the present invention has a structure in which the 3-position hydroxyl group of 4-methylergost-7-en-3-ol and the 1-position hydroxyl group of D-glucose are dehydrated and condensed.
- the composition of the present invention contains the compound of the present invention in an amount of 0.001% by mass or more, preferably 0.01% by mass or more, more preferably 0.1% by mass or more on a dry mass basis. It is an extract of a lily plant or a fraction thereof.
- the upper limit of the content of the compound of the present invention contained in the composition of the present invention is not particularly limited, and may be, for example, 50% by mass, 70% by mass, or 90% by mass.
- the compound of the present invention or a composition containing the same belongs to, for example, a plant belonging to the family Liliaceae, and extracts a fraction containing the compound from a plant containing the compound of the present invention or a part thereof or a crushed product thereof with an organic solvent. Alternatively, it can be produced by extraction and concentration using hot water.
- Examples of the plants belonging to the lily family include plants belonging to the genus Aloe or Allium. Aloe vera plants (Aloe barbadensis Miller), Aloe ferox Smirror (Aloe ferox Miller), Aloe africana Miller, Aloe arborescen Miller var. Aloe spicata Baker). In the production of the compound of the present invention or a composition containing the same, the whole plant may be used, but it is preferable to use the mesophyll (transparent gel portion). Such a plant or a part thereof is preferably crushed using a homogenizer or the like, and subjected to liquid filtration, and extracted with an organic solvent or hot water.
- organic solvent examples include alcohols such as methanol, ethanol and butanol; esters such as methyl acetate, ethyl acetate, propyl acetate, and butyrate acetate; ketones such as acetone and methyl isobutyl ketone; getyl ether; Ethers such as oil ethers; hydrocarbons such as hexane, cyclohexane, toluene and benzene; halogenated hydrocarbons such as tetrachloride carbon, dichloromethane and chloroform; complex ring compounds such as pyridine, ethylene glycol and the like.
- alcohols such as methanol, ethanol and butanol
- esters such as methyl acetate, ethyl acetate, propyl acetate, and butyrate acetate
- ketones such as acetone and methyl isobutyl ketone
- getyl ether Ethers such as oil ethers
- an extraction method a method commonly used for extracting a plant component can be used. Usually, 1 to 300 parts by mass of organic solvent is used per 1 part by mass of fresh or dried plant, and the mixture is heated to reflux below the boiling point of the solvent with stirring or shaking, or is subjected to ultrasonic extraction at room temperature. Method. The extract can be separated into insolubles by a suitable method such as filtration or centrifugation to obtain a crude extract.
- the crude extract can be purified by various types of chromatography, for example, normal phase or reverse phase silica gel column chromatography.
- reverse-phase silica gel column chromatography when a gradient of a mixed solution of methanol and water is used as an elution solvent, the compound of the present invention is eluted with about 95% methanol.
- the obtained fraction can be further purified by HPLC or the like.
- the compound of the present invention can also be produced by condensing D-glucose with 4-methylergosto-7-en-3-ol.
- 4-Methylergost-7-en-3-ol can be obtained by extracting and purifying from plants. .
- the condensation of D-glucose with 4-methylergost-7-en-3-ol is described in, for example, Experimental Chemistry Course, 4th Edition, 26, 1992 (described on pages 272, 297, and 342), Can be performed in combination. That is, after complete acetylation of D-glucose, the anomeric position is converted to ⁇ -promide.
- the compound of the present invention has an action of lowering the level of hemoglobin Ale, and as a result, can control blood glucose level for a long period of time. Therefore, it can be used as an active ingredient of a hyperglycemia improving agent.
- the leaves of aloe vera conventionally contain barobaroin and aloe-emodin, which have a laxative effect, and are considered to be unfavorable as drugs or foods and drinks that do not expect a laxative effect.
- the composition of the present invention can be obtained by extracting and fractionating from aloe vera leaf (transparent gel portion) which can be safely ingested through eating experience, and therefore does not contain barbaroin or aloe-emodin. And an effective amount of the compound of the present invention. Therefore, the composition of the present invention is also suitable as an active ingredient of a hyperglycemia improving agent.
- the compound or composition of the present invention can be used as it is as an active ingredient of the drug or food or beverage of the present invention.
- the composition of the present invention can be stored and used as a powder by freeze-drying or spray-drying by a conventional method, which may be a solution.
- the drug of the present invention is orally or parenterally administered to mammals including humans, in combination with the compound or composition of the present invention or a pharmaceutically acceptable pharmaceutical carrier. be able to.
- the compound of the present invention can be pharmaceutically acceptable salts.
- Pharmaceutically acceptable salts include both metal salts (inorganic salts) and organic salts, a list of which can be found in Remington's Pharmaceutical Sciences, 17th Edition, 1418. Page, 1985 ".
- inorganic acid salts such as hydrochloride, sulfate, phosphate, diphosphate, hydrobromide and sulfate, malate, maleate, fumaric acid Unlimited organic salts such as salt, tartrate, succinate, citrate, acetate, lactate, methanesulfonate, P-toluenesulfonate, pamoate, salicylate and stearate Included.
- salts of metals such as sodium, potassium, calcium, magnesium and aluminum, and salts with amino acids such as lysine can also be used.
- the present invention includes a solvate such as a hydrate of the above compound or a pharmaceutically acceptable salt thereof.
- the formulation of the drug of the present invention is not particularly limited and can be appropriately selected depending on the purpose of treatment. Specifically, tablets, pills, powders, solutions, suspensions, emulsions, granules, capsules Preparations, syrups, suppositories, injections, ointments, patches, eye drops, nasal drops and the like.
- An additive such as a solvent for the agent can be used.
- the compound or composition of the present invention may be used in combination with another drug having an effect of improving hyperglycemia as long as the effects of the present invention are not impaired.
- the amount of the compound or composition of the present invention contained in the drug of the present invention is not particularly limited and may be appropriately selected.
- the amount of the compound of the present invention may be 0.0001 to 0.001 in the preparation. 10% by mass, preferably 0.01 to 1% by mass. / 0 , particularly preferably 0.05 to 1% by mass.
- the agent of the present invention is useful for treating or preventing a disease caused by a hyperglycemic condition, for example, diabetes and preglycaemia (a condition suspected of diabetes).
- a hyperglycemic condition for example, diabetes and preglycaemia (a condition suspected of diabetes).
- hyperglycemic status can also be used to prevent the development of diabetes.
- the medicament of the present invention contains the above-mentioned agent of the present invention (hyperglycemia improving agent), and is used for treatment of diseases caused by hyperglycemia, such as diabetes and prediabetes (a condition suspected as diabetes). Or it is useful for prevention. In particular, it can be used to prevent the onset of diabetes from a hyperglycemic state. Furthermore, the medicament of the present invention is capable of treating or preventing various diseases and complications caused by a hyperglycemic state and reducing the risk of these diseases and complications.
- the hyperglycemic state is a state other than the normal region, and the normal region is generally a fasting blood glucose level of 110 mg / dl or less and a blood glucose level one hour after a 75 g glucose load.
- the blood glucose level at 160 mg / dl or less and 120 mgZdl or less at 2 hours is in a state of sickness (Japanese clinical practice, 806, 1, 28-35, 2002).
- the agent of the present invention is suitably used for the treatment of a patient whose hemoglobin Ale value is higher than that of a healthy individual, for example, a patient whose hemoglobin Ale value is 5.8% or more.
- the administration time of the drug or medicament of the present invention is not particularly limited, and the administration time can be appropriately selected according to the method of treating the target disease.
- the administration form is preferably determined according to the form of the preparation, the age and sex of the patient, other conditions, the degree of symptoms of the patient, and the like.
- the dose of the active ingredient of the drug of the present invention is appropriately selected depending on the usage, the age of the patient, the sex, the degree of the disease, other conditions, and the like.
- the amount of the compound of the present invention as an active ingredient is preferably in the range of 0.01 to: LOmgZkgZ days, more preferably in the range of 0.1 to LmgZkgZ days.
- the amount is preferably such that the dry weight of the composition is 0.1 to: LOOOmgZkgZ days, more preferably 1 to: LOOmgZkgZ days.
- administration can be carried out once or multiple times a day.
- the drug or medicament of the present invention, or the compound or composition of the present invention, which is an active ingredient thereof, can also be contained in food or drink (beverage or food).
- the food and drink are not particularly limited in form and properties as long as they can be orally ingested without impairing the effects of the active ingredients, and use raw materials usually used in foods and drinks except for containing the active ingredients. And can be manufactured by ordinary methods.
- the amount of the compound or the composition of the present invention contained in the food or drink of the present invention is not particularly limited and may be appropriately selected.
- the amount is preferably from 1 to 1% by mass, more preferably from 0.001 to 1% by mass, particularly preferably from 0.005 to 1% by mass.
- “amelioration of hyperglycemia” means to improve or prevent various health harms caused by hyperglycemia, and "hyperglycemia”.
- the term “prevention”, “suppression of blood sugar rise”, “improvement of blood sugar rise”, “prevention of blood sugar rise”, “improvement of high hemoglobin Ale value”, and the like have the same meaning as “improvement of hyperglycemia” in the present invention. Examples can be given.
- the food or drink of the present invention is useful for preventing diseases caused by a hyperglycemic state, for example, diabetes and prediabetes (a state suspected of diabetes). In particular, it can be used to prevent the onset of diabetes from a hyperglycemic state. Furthermore, the food and drink of the present invention can prevent various diseases and complications caused by hyperglycemia and reduce the risk of these diseases and complications.
- Various diseases caused by such a hyperglycemic state include complications such as diabetic retinopathy, diabetic nephropathy, diabetic neuropathy, diabetic gangrene, stroke caused by diabetes, and diabetes. Myocardial infarction and the like.
- the food and drink of the present invention include a food and drink with a label indicating that it is used for improving hyperglycemia, for example, a compound containing a compound having a hyperglycemic improving effect, which is labeled as "for improving hyperglycemia".
- a food and drink with a label indicating that it is used for improving hyperglycemia for example, a compound containing a compound having a hyperglycemic improving effect, which is labeled as "for improving hyperglycemia”.
- the compound or composition of the present invention has a hyperglycemic ameliorating effect, it is considered that the indication of amelioration of hyperglycemia also has the meaning of suppressing an increase in blood glucose. Therefore, the food and drink of the present invention can be labeled as “for suppressing blood sugar rise”. That is, the display for improving hyperglycemia may be such a display for "suppressing increase in blood glucose”.
- the wording used for performing the display as described above is not limited to only the wording "for improving hyperglycemia” or the wording "for suppressing blood sugar rise”. It goes without saying that any wording that expresses the effect of improving hyperglycemia or suppressing or increasing the blood sugar level is included in the scope of the present invention. Such wording includes, for example, various uses such as letting consumers recognize the effects of improving hyperglycemia or suppressing a rise in blood glucose level. A display based on this is also possible. For example, a display such as "suitable for those who have begun to be concerned about blood sugar levels", "reducing the risk factors (risks) of lifestyle-related diseases such as diabetes, and helping to eliminate” can be given.
- the "display” means all actions for informing the consumer of the above-mentioned use, and if the display can recall or analogize the above-mentioned use, the purpose of the display and the display of the display are considered. Regardless of the content, the object to be displayed, the medium, etc., all fall under the “display” of the present invention. However, it is preferable to display the information in an expression that allows the consumer to directly recognize the use.
- the act of describing the above-mentioned use on the product or the packaging of the product according to the food and drink of the present invention and the transfer or delivery of the product or the product with the above-mentioned use described on the packaging of the product for the transfer or delivery Import, advertising on goods, price list or transaction documents, exhibiting or distributing the above-mentioned use, or describing the above-mentioned use in information containing these, and electromagnetically (such as the Internet) )
- the actions provided by the method can be exemplified.
- the display is preferably a display approved by the government or the like (for example, a display that is approved based on various systems determined by the government and is performed in a form based on such approval).
- a display that is approved based on various systems determined by the government and is performed in a form based on such approval.
- labeling as health foods, functional foods, enteral nutrition foods, special use foods, nutritional function foods, quasi-pharmaceutical products, and the like can be exemplified.
- Approved indications for example, foods for specified health use and indications approved under a similar system can be exemplified. Examples of the latter can include labeling as food for specified health use, labeling as food for conditional health use, labeling that affects the structure and function of the body, labeling for reducing disease risk, etc.
- the labeling as food for specified health use (especially the labeling of health use) specified in the Health Promotion Law Enforcement Regulations (Ordinance No. 86 of the Ministry of Health, Labor and Welfare on April 30, 2003) and similar Indications can be listed as typical examples.
- the mixed solution of ethyl ethyl Z-butanol and the aqueous layer were separated to collect the mixed solution of ethyl ethyl Z-butanol.
- the weight of the ethyl acetate Z-butanol mixture extract obtained by concentrating this ethyl acetate-Z-butanol mixture under reduced pressure was 13.5 g.
- the crude product A is diluted. Investigation using layer chromatography (Silica Genole 60F254 and RP-18F2543, manufactured by Merck) indicated that the separation method by reversed-phase silica gel column chromatography using methanol was appropriate. Then, the above crude product A was dissolved in 1 ml of a mixture of form-form Z in methanol (1: 1), and the solution was adsorbed on a column filled with 180 g of Cosmoseal 140 (manufactured by Nacalai Tester). , 85% methanol solution, 600 ml, 95% methanol solution, 600 ml, 100% methanol, 100 ml.
- the thin-layer chromatography of compound 1 shows an Rf value very close to that of ⁇ -sitosterol darcoside, indicating that compound 1 is a glycoside having one molecule of sugar bound to the aglycone moiety.
- Compound 1 was subjected to methanolysis, and then measured using GC-MS as a TMS derivative.
- TMS derivative of the sugar moiety of Compound 1 was measured, the main peak was observed at retention times of 14.28 min, 14.61 min, and 16.34 min, and was the main peak of standard glucose (manufactured by Nacalai Tester). It almost coincided with 14.27min, 14.60min and 16.33min.
- no peak corresponding to the main peaks of the standard galatatoses (Kishida) and the standard xylose (Kishida) was found.
- the type of sugar contained in Compound 1 was glucose.
- Compound 1 was a glycoside in which one molecule of glucose was bound to the aglycone moiety.
- Compound 1 was measured by 13 C-NMR (125 MHz, CDC1).
- FIGS. 1 and 2 The measurement conditions and results are as follows. Also, 3-acetoxy-14-methylergost-17-ene used as a standard substance was produced by extracting and purifying from aloe, confirming the structure by 13 C-NMR, and then acetylating.
- Aloe vera leaf (transparent gel portion) was dried by heating, and 0.3 ml of the pulverized dried aloe vera powder was added to 60 ml of water, followed by heating to reflux at 95 ° C for 5 hours. The extract was centrifuged at 1500 rpm for 20 minutes, and the supernatant was freeze-dried to obtain 75 mg of a crude extract. It was confirmed by thin layer chromatography that the crude extract contained 3--0- ⁇ -D-darcoviranosyl 4-methylergost-17-en-3-ol.
- Aloe vera leaf (transparent gel portion) is dried by heating, pulverized, and further dried, and dried. 21 kg of powdered aloe vera powder is added to 90 liters of a mixture of form-Z methanol mixture (2: 1), and then cooled to room temperature. Then, 90 liters of a mixed solution of formaldehyde Z methanol (2: 1) was added again to the filtration residue, and the same operation was performed a total of four times. The obtained filtrate (350 L) was concentrated at 28 ° C. to finally obtain 784 g of a crude extract.
- mice Six-week-old male dbZdb mice (purchased from CLEA Japan) were used as type II diabetes model mice. The mice were grouped into 7 mice per group. After dissolving the test sample in DMSO, the concentration of 3-O- ⁇ -D-darcoviranosyl-4-methylergost-7-en-3ol was adjusted to 15 gZml with physiological saline. The final DMSO concentration was adjusted to 0.2%. Once a day, add 1 ml of the test sample solution to the type II diabetes model mouse using a sonde. It was orally administered every day. A solution containing no test sample was used as a negative sample. The fasting blood glucose level and the normal blood glucose level were measured over time using Antsense II (manufactured by Bayer Sankyo). Fasting blood glucose was measured after 15 hours of fasting.
- FIG. 3 and FIG. 4 show the temporal changes in the normal blood glucose level and the fasting blood glucose level during the administration of the test sample.
- a sharp increase in the blood glucose level was observed even when the normal and fasting blood glucose levels were slightly different from each other. The effect of suppressing the increase in the value was observed.
- test sample was 3-O- ⁇ -D-darcoviranosyl-4-methylergost-7-en-3-ol produced in Production Example 1.
- mice Six-week-old male dbZdb mice (purchased from CLEA Japan) were used as type II diabetes model mice. The mice were grouped into 7 mice per group. After dissolving the test sample in DMSO, adjust the concentration of 3-O- ⁇ -D-darcoviranosyl-4-methylergost-7-en-3-ol with physiological saline to 1, 5, 15 / z gZml. did. The final DMSO concentration was adjusted to 0.2%. Each type of test sample solution was orally administered to the type II diabetes model mouse once a day using a probe every day. In addition, the! / ⁇ solution containing no test sample was used as a negative sample. On day 35 from the start of administration, hemoglobin Ale was measured using DCA2000 (manufactured by Bayer Sankyo).
- Table 1 shows the measurement results of hemoglobin Ale on day 35 from the start of administration. Continuous administration of 5 or 15 g of test sample showed a statistically significant decrease in hemoglobin Ale compared to the value of hemoglobin Ale when the negative sample was administered. It was shown to be effective. In addition, during the administration period, symptoms of side effects and No abnormalities were observed in the body weight or pathological findings that caused the glycemic condition.
- mice Six-week-old male dbZdb mice (purchased from CLEA Japan) were used as type II diabetes model mice. The mice were grouped into 7 mice per group. After dissolving the test sample in DMSO, the concentration of the crude extract A was adjusted to 25, 100, 200 / zgZml with physiological saline. The final DMSO concentration was adjusted to 0.2%. Each type of test sample solution was orally administered to the type II diabetes model mouse once a day using a sonde every day. The test sample was not included and the solution was regarded as a negative sample. On the 35th day from the start of administration, hemoglobin Ale was measured using DCA2000 (manufactured by Bayer Sankyo).
- Table 2 shows the measurement results of hemoglobin Ale on day 35 from the start of administration.
- Continuous administration of 100 or 200 ⁇ g of test sample showed a decrease in hemoglobin Ale compared to that of moglobin Ale, indicating a statistically significant long-term blood glucose control effect.
- the compound of the present invention can be safely administered or ingested without causing hypoglycemia, and has a long-term blood glucose level controlling effect of lowering hemoglobin Ale level.
- the composition of the present invention can be produced using a plant of the family Liliaceae, for example, a genus Aloe or Allium, which is a plant that can be safely ingested from food experience and is easily available.
- the composition of the present invention contains an effective amount of the compound of the present invention.
- the composition does not contain barbaroin or aloe-emodin which is not preferable as a medicine or food and drink.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Botany (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Polymers & Plastics (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Food Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Steroid Compounds (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005518606A JP3883563B2 (ja) | 2004-03-31 | 2005-03-30 | 4−メチルエルゴスト−7−エン−3−オール骨格を有する配糖体及び高血糖改善剤 |
US10/564,464 US7534770B2 (en) | 2004-03-31 | 2005-03-30 | Glycoside having 4-methylergost-7-en-3-ol skeleton and hyperglycemia improving agent |
CA002533784A CA2533784C (en) | 2004-03-31 | 2005-03-30 | Glycoside having 4-methylergost-7-en-3-ol skeleton and hyperglycemia improving agent |
EP05727327A EP1731527B1 (en) | 2004-03-31 | 2005-03-30 | Glycoside having 4-methylergost-7-en-3-ol skeleton and drug for ameliorating hyperglycemia |
US12/180,241 US8486462B2 (en) | 2004-03-31 | 2008-07-25 | Glycoside having 4-methylergost-7-en-3-ol skeleton and hyperglycemia improving agent |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004103684 | 2004-03-31 | ||
JP2004-103684 | 2004-03-31 | ||
JP2004-112108 | 2004-04-06 | ||
JP2004112108 | 2004-04-06 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/564,464 A-371-Of-International US7534770B2 (en) | 2004-03-31 | 2005-03-30 | Glycoside having 4-methylergost-7-en-3-ol skeleton and hyperglycemia improving agent |
US12/180,241 Division US8486462B2 (en) | 2004-03-31 | 2008-07-25 | Glycoside having 4-methylergost-7-en-3-ol skeleton and hyperglycemia improving agent |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005095436A1 true WO2005095436A1 (ja) | 2005-10-13 |
Family
ID=35063719
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/006019 WO2005095436A1 (ja) | 2004-03-31 | 2005-03-30 | 4-メチルエルゴスト-7-エン-3-オール骨格を有する配糖体及び高血糖改善剤 |
Country Status (7)
Country | Link |
---|---|
US (2) | US7534770B2 (ja) |
EP (1) | EP1731527B1 (ja) |
JP (1) | JP3883563B2 (ja) |
KR (1) | KR100743852B1 (ja) |
CA (1) | CA2533784C (ja) |
RU (1) | RU2315770C1 (ja) |
WO (1) | WO2005095436A1 (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006123464A1 (ja) * | 2005-05-17 | 2006-11-23 | Morinaga Milk Industry Co., Ltd. | 膵臓機能改善のための医薬又は飲食品 |
WO2007034851A1 (ja) * | 2005-09-22 | 2007-03-29 | Morinaga Milk Industry Co., Ltd. | 内臓脂肪蓄積抑制剤 |
WO2007043305A1 (ja) * | 2005-09-30 | 2007-04-19 | Morinaga Milk Industry Co., Ltd. | インスリン抵抗性改善剤 |
WO2007043302A1 (ja) | 2005-09-30 | 2007-04-19 | Morinaga Milk Industry Co., Ltd. | インスリン抵抗性改善剤 |
WO2007043306A1 (ja) * | 2005-09-30 | 2007-04-19 | Morinaga Milk Industry Co., Ltd. | インスリン抵抗性改善剤 |
WO2010058794A1 (ja) * | 2008-11-19 | 2010-05-27 | 森永乳業株式会社 | 抗酸化剤 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2742947C (en) * | 2008-11-19 | 2013-12-17 | Morinaga Milk Industry Co., Ltd. | Antioxidant |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0970278A (ja) * | 1995-09-05 | 1997-03-18 | Kowa Chem Ind Co Ltd | ギムネマ・イノドラム焙煎茶及びその製法 |
WO2003059360A1 (en) * | 2002-01-11 | 2003-07-24 | Medical Isotopes, Inc. | Novel cholesterol absorption lowering agents |
JP2003284185A (ja) * | 2002-03-27 | 2003-10-03 | Sony Corp | ステレオマイクロホン装置 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60214741A (ja) | 1984-04-05 | 1985-10-28 | Toyo Yakushiyoku Kogyo Kk | 血糖降下剤 |
JPH01312978A (ja) | 1988-06-13 | 1989-12-18 | Shiro Kobayashi | 飲料用及び添加用食品 |
JPH05247086A (ja) | 1992-01-31 | 1993-09-24 | Kowa Kagaku Kogyo Kk | 1−〔3β−(16β,28−ジヒドロキシオレアン−12−エン)オキシ〕−2−O−β−D−グルコース−β−D−グルクロン酸及びその製造方法 |
JPH06319498A (ja) * | 1993-05-12 | 1994-11-22 | Hirata Nouen:Kk | アロエジュース飲料の製造方法 |
JP3685833B2 (ja) | 1995-02-06 | 2005-08-24 | 日本メナード化粧品株式会社 | 免疫抑制改善剤 |
JP3828953B2 (ja) | 1995-05-24 | 2006-10-04 | 日本製粉株式会社 | リパーゼ阻害剤 |
JP3752000B2 (ja) | 1995-08-21 | 2006-03-08 | ユリカ株式会社 | アロエ葉皮由来のレクチン活性蛋白質 |
CA2236171A1 (en) | 1995-10-31 | 1997-05-09 | Merck & Co., Inc. | Triterpene derivatives with immunosuppressant activity |
JP3605924B2 (ja) | 1996-02-20 | 2004-12-22 | 三菱化学株式会社 | 食品の臭気マスキング剤および該マスキング剤を用いた食品の臭気マスキング方法 |
JP3966922B2 (ja) | 1996-07-18 | 2007-08-29 | 一丸ファルコス株式会社 | 線維芽細胞増殖促進剤 |
JPH1036271A (ja) | 1996-07-25 | 1998-02-10 | Kureha Chem Ind Co Ltd | Hsp27ファミリーに属するタンパク質のアロイン誘導体含有合成抑制剤 |
JPH1045604A (ja) | 1996-07-30 | 1998-02-17 | Kureha Chem Ind Co Ltd | アロイン誘導体含有hsp47合成抑制剤 |
JPH10120576A (ja) | 1996-10-16 | 1998-05-12 | Kureha Chem Ind Co Ltd | Hsp60ファミリーに属するタンパク質のアロイン誘導体含有合成抑制剤 |
JPH10330266A (ja) | 1997-06-02 | 1998-12-15 | Kotarou Kanpo Seiyaku Kk | インスリン作用増強活性組成物 |
US6133440A (en) | 1997-10-10 | 2000-10-17 | Univera Pharmaceuticals, Inc. | Process for the preparation of immunomodulatory polysaccharides from aloe |
US6506387B1 (en) * | 1999-04-28 | 2003-01-14 | Paxa N.V. | Method for preparing aloin by extraction |
JP4393717B2 (ja) | 2001-01-04 | 2010-01-06 | 株式会社ユース・テクノコーポレーション | 代謝異常改善方法およびそのための組成物 |
JP2002371003A (ja) | 2001-06-15 | 2002-12-26 | Kikkoman Corp | 血糖値上昇抑制剤 |
JP3790686B2 (ja) | 2001-08-03 | 2006-06-28 | 独立行政法人理化学研究所 | 血糖降下剤 |
JP2003095941A (ja) | 2001-09-26 | 2003-04-03 | Ito En Ltd | 糖質消化酵素阻害剤、血糖値上昇抑制剤、肥満治療予防剤、糖尿病治療予防剤、健康飲食物 |
JP2003286185A (ja) | 2002-03-29 | 2003-10-07 | Daily Foods Kk | アロエベラ圧搾液及び該圧搾液を有効成分とする血糖値降下剤 |
US6884783B2 (en) | 2002-05-03 | 2005-04-26 | Unigen Pharmaceuticals, Inc. | 7-Hydroxy chromones as potent antioxidants |
-
2005
- 2005-03-30 JP JP2005518606A patent/JP3883563B2/ja active Active
- 2005-03-30 CA CA002533784A patent/CA2533784C/en active Active
- 2005-03-30 RU RU2006108792/04A patent/RU2315770C1/ru not_active IP Right Cessation
- 2005-03-30 WO PCT/JP2005/006019 patent/WO2005095436A1/ja not_active Application Discontinuation
- 2005-03-30 KR KR1020067001515A patent/KR100743852B1/ko active IP Right Grant
- 2005-03-30 EP EP05727327A patent/EP1731527B1/en active Active
- 2005-03-30 US US10/564,464 patent/US7534770B2/en active Active
-
2008
- 2008-07-25 US US12/180,241 patent/US8486462B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0970278A (ja) * | 1995-09-05 | 1997-03-18 | Kowa Chem Ind Co Ltd | ギムネマ・イノドラム焙煎茶及びその製法 |
WO2003059360A1 (en) * | 2002-01-11 | 2003-07-24 | Medical Isotopes, Inc. | Novel cholesterol absorption lowering agents |
JP2003284185A (ja) * | 2002-03-27 | 2003-10-03 | Sony Corp | ステレオマイクロホン装置 |
Non-Patent Citations (4)
Title |
---|
"Health Promotion Law", 30 April 2003 |
ABOU-ZEID A.H.S. ET AL: "Chemical and Biological Study for the Leavels of some Musa Species.", EGYPT.J.PHARM.SCI., vol. 39, no. 4-6, 1998, pages 179 - 198, XP002990128 * |
See also references of EP1731527A4 |
YEH G.Y. ET AL: "Systematic Review of Herbs and Dietary Supplements for Glycemic Control in Diabetes.", DIABETES CARE., vol. 26, no. 4, 2003, pages 1277 - 1294, XP002990127 * |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7531520B2 (en) | 2005-05-17 | 2009-05-12 | Morinaga Milk Industry Co., Ltd. | Drug and food or drink for improving pancreatic functions |
EP1882477A4 (en) * | 2005-05-17 | 2012-07-04 | Morinaga Milk Industry Co Ltd | DRUGS, FOOD OR BEVERAGE FOR ENHANCED PANCREATIC FUNCTIONS |
WO2006123464A1 (ja) * | 2005-05-17 | 2006-11-23 | Morinaga Milk Industry Co., Ltd. | 膵臓機能改善のための医薬又は飲食品 |
EP1882477A1 (en) * | 2005-05-17 | 2008-01-30 | Morinaga Milk Industry Co., Ltd. | Drugs, food or drink for improving pancreatic functions |
WO2007034851A1 (ja) * | 2005-09-22 | 2007-03-29 | Morinaga Milk Industry Co., Ltd. | 内臓脂肪蓄積抑制剤 |
US7846905B2 (en) | 2005-09-22 | 2010-12-07 | Morinaga Milk Industry Co., Ltd. | Agent for inhibiting visceral fat accumulation |
WO2007043306A1 (ja) * | 2005-09-30 | 2007-04-19 | Morinaga Milk Industry Co., Ltd. | インスリン抵抗性改善剤 |
WO2007043302A1 (ja) | 2005-09-30 | 2007-04-19 | Morinaga Milk Industry Co., Ltd. | インスリン抵抗性改善剤 |
US7947669B2 (en) | 2005-09-30 | 2011-05-24 | Morinaga Milk Industry Co., Ltd. | Agent for improving insulin resistance |
WO2007043305A1 (ja) * | 2005-09-30 | 2007-04-19 | Morinaga Milk Industry Co., Ltd. | インスリン抵抗性改善剤 |
US8236769B2 (en) | 2005-09-30 | 2012-08-07 | Morinaga Milk Industry Co., Ltd. | Agent for improving insulin resistance |
US8575142B2 (en) | 2005-09-30 | 2013-11-05 | Morinaga Milk Industry Co., Ltd. | Agent for improving insulin resistance |
WO2010058794A1 (ja) * | 2008-11-19 | 2010-05-27 | 森永乳業株式会社 | 抗酸化剤 |
JP4580041B2 (ja) * | 2008-11-19 | 2010-11-10 | 森永乳業株式会社 | 抗酸化剤 |
JPWO2010058794A1 (ja) * | 2008-11-19 | 2012-04-19 | 森永乳業株式会社 | 抗酸化剤 |
US8486899B2 (en) | 2008-11-19 | 2013-07-16 | Morinaga Milk Industry Co., Ltd. | Antioxidant |
Also Published As
Publication number | Publication date |
---|---|
US8486462B2 (en) | 2013-07-16 |
RU2006108792A (ru) | 2007-09-27 |
US20080044500A1 (en) | 2008-02-21 |
EP1731527B1 (en) | 2012-10-10 |
EP1731527A1 (en) | 2006-12-13 |
US7534770B2 (en) | 2009-05-19 |
KR20060052860A (ko) | 2006-05-19 |
EP1731527A4 (en) | 2009-07-22 |
US20090075913A1 (en) | 2009-03-19 |
CA2533784C (en) | 2009-09-15 |
JP3883563B2 (ja) | 2007-02-21 |
CA2533784A1 (en) | 2005-10-13 |
JPWO2005095436A1 (ja) | 2007-08-16 |
KR100743852B1 (ko) | 2007-08-02 |
RU2315770C1 (ru) | 2008-01-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3905913B2 (ja) | 高血糖改善のための医薬及び飲食品 | |
JP3924310B2 (ja) | 高血糖改善のための医薬及び飲食品 | |
JP3883563B2 (ja) | 4−メチルエルゴスト−7−エン−3−オール骨格を有する配糖体及び高血糖改善剤 | |
JP4065016B2 (ja) | 膵臓機能改善のための医薬又は飲食品 | |
JP4169777B2 (ja) | インスリン抵抗性改善剤 | |
WO2007043294A9 (ja) | 内臓脂肪蓄積抑制剤 | |
JP4162703B2 (ja) | 内臓脂肪蓄積抑制剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200580000801.7 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005518606 Country of ref document: JP |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005727327 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10564464 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020067001515 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2533784 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006108792 Country of ref document: RU |
|
WWP | Wipo information: published in national office |
Ref document number: 1020067001515 Country of ref document: KR |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
WWP | Wipo information: published in national office |
Ref document number: 2005727327 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10564464 Country of ref document: US |